NEK7 Degradation Reaches Human Pharmacodynamic Proof
Monte Rosa reported randomized Phase 1 GFORCE-1 data in 108 obese adults with elevated cardiovascular risk. Four weeks of oral NEK7-directed molecular glue MRT-8102 produced 80–90% median NEK7 degradation and broad reductions in inflammatory…
